Zhongzhi Pharmaceutical Holdings (HKG:3737) plans to unwind its contractual arrangements with Zhongshan Zhongzhi Chinese Medicine Herb in Pieces as it can now directly hold equity interest in the latter, a Friday Hong Kong bourse filing said.
Zhongzhi Chinese Medicine Herb in Pieces is mainly engaged in the production of traditional and modern decoction pieces in China and is a major Chinese operating subsidiary of the group.
The company was not allowed to hold a direct interest in Zhongzhi Chinese Medicine Herb in Pieces due to the restrictions placed by the Foreign Investment Catalogue and had hence entered into contractual agreements to take management of and economic benefits from it.
As the said restrictions are now lifted in the Catalogue of Restricted Foreign Investment Industries (2024 version) issued by the National Development and Reform Commission on Sept. 8, the company now intends to hold equity interest in the Zhongzhi Chinese Medicine Herb in Pieces.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。